Development and validation of the CHI-CAT score: a novel tool for assessing cancer-associated venous thromboembolism risk in China
Xiaoli Qin, Xiurong Gao, Qin He, Min Xu, Yujie Yang, Qian Jiang · 2025
Read Development and validation of the CHI-CAT score: a novel tool for assessing cancer-associated venous thromboembolism risk in China by Xiaoli Qin, Xiurong Gao, Qin He, Min Xu, Yujie Yang, Qian Jiang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751137.txt.
Description
Xiaoli Qin and co-authors present a 2025 study building a clot-risk score for Chinese cancer patients. Cancer and its treatment raise the risk of venous thromboembolism, and prevention helps only if aimed at the right patients. The widely used Khorana score was built on Western data, so the team derived a local rival, the CHI-CAT score.
They reviewed 868 patients treated at a Chengdu hospital between 2022 and 2023. A derivation group of 428 patients supplied the traits that best separated those who clotted from those who did not. A second group validated the score, and standard accuracy measures compared it with Khorana. The authors argue a home-grown tool fits Chinese practice better. Hospitals can use it to target blood-thinning prevention.
Catalog record
| CREATOR | Xiaoli Qin, Xiurong Gao, Qin He, Min Xu, Yujie Yang, Qian Jiang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |